Development of slow release reagent of NFkB decoy oligodeoxynucleotides for the treatment of rheumatic arthritis
治疗风湿性关节炎的NFkB诱饵寡脱氧核苷酸缓释试剂的研制
基本信息
- 批准号:13558109
- 负责人:
- 金额:$ 8.13万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2001
- 资助国家:日本
- 起止时间:2001 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We attempted to prolong release of NFkB oligodeoxynudeotid.es without degradation. First, we tested the efficiency of introduction of FITC-labeled oligonucleotides into cultured cells using atelocollagen. No fluorescence was detected at 48 hours after the transfer to HeLa, BHK-21 and human tongue cancer cell line SAS. Then, we developed HVJ (hemagglutinating virus of Japan ; Sendai virus) envelope vector which can introduce synthetic oligonucleotides, proteins, peptides and chemical drugs as well as genes. FITC-labeled oligonucleotides were incorporated into HVJ envelope vector by the treatment of mild detergent and centrifugation. Ten minutes after incubation of those cultured cells described above with the HVJ envelope vector, fluorescence was observed in almost all the nuclei of the cells. When NFkB decoy oligonucleotides were introduced into cancer cells such as SAS and HeLa cells using HVJ envelope vector, apoptosis after irradiation was enhanced by the suppression of NFkB-induced … More gene expression. When FITC-labeled NFkB decoy oligonucleotides were introduced into the joint space of Cynomolgus monkeys using HVJ envelope vector, fluorescence was detected at both synovium and articular cartilage. Next, HVJ envelope vector was embedded with various polymers. First, without polymer, HVJ envelope vector reaches spleen by intravenous injection and FITC-oligonucleotides were detected at the marginal zone of mouse spleen. Then, the vector containing luciferase gene was decorated with protamine suifate and the complex was injected into tail vein of mouse. Gene expression was detected exclusively in lung, not in spleen. Furthermore, when HVJ envelope vector mixed with heparin was injected into muscle or brain directly, gene expression was approximately 5 fold increased than that without heparin. The effect of polymers on slow release of the vector is being investigated, but we have got preliminary data suggesting that cationic polymers may enhance slow release of HVJ envelope vector. Less
我们尝试延长 NFkB 寡脱氧核苷酸的释放而不降解。首先,我们测试了使用去端肽胶原将 FITC 标记的寡核苷酸引入培养细胞的效率。转移至HeLa、BHK-21和人舌癌细胞系SAS后48小时未检测到荧光。然后,我们开发了HVJ(日本血凝病毒;仙台病毒)包膜载体,可以导入合成的寡核苷酸、蛋白质、肽和化学药物以及基因。通过温和去污剂处理和离心,将 FITC 标记的寡核苷酸整合到 HVJ 包膜载体中。将上述培养的细胞与HVJ包膜载体一起温育10分钟后,几乎在所有细胞的细胞核中都观察到荧光。当使用 HVJ 包膜载体将 NFkB 诱饵寡核苷酸引入 SAS 和 HeLa 细胞等癌细胞时,通过抑制 NFkB 诱导的基因表达,增强了辐射后的细胞凋亡。当使用 HVJ 包膜载体将 FITC 标记的 NFkB 诱饵寡核苷酸引入食蟹猴的关节间隙时,滑膜和关节软骨均检测到荧光。接下来,HVJ 包膜载体嵌入各种聚合物。首先,在没有聚合物的情况下,HVJ包膜载体通过静脉注射到达脾脏,并在小鼠脾脏的边缘区检测到FITC-寡核苷酸。然后,用硫酸鱼精蛋白修饰含有荧光素酶基因的载体,并将复合物注射到小鼠尾静脉中。基因表达仅在肺中检测到,而不是在脾脏中检测到。此外,当与肝素混合的HVJ包膜载体直接注射到肌肉或大脑中时,基因表达比没有肝素的情况增加约5倍。聚合物对载体缓慢释放的影响正在研究中,但我们已经得到初步数据表明阳离子聚合物可以增强HVJ包膜载体的缓慢释放。较少的
项目成果
期刊论文数量(40)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kaneda, Y.: "Pharmaceutical Gene Delivery Systems"Alain Rolland and Sean Sullivan(in press). (2003)
Kaneda, Y.:“药物基因传递系统”Alain Rolland 和 Sean Sullivan(出版中)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Taniyama, Y., Tachibana, K., Hiraoka, K., Nainba, T., Yamasaki, K., Hashiya, N., Aoki, M., Ogihara, T., Kaneda, Y., and Morishita, R.: "Local delivery of plasmid DNA into rat carotid artery using ultrasound"Circulation. 105. 1233-1239 (2002)
Taniyama, Y.、Tachibana, K.、Hiraoka, K.、Nainba, T.、Yamasaki, K.、Hashiya, N.、Aoki, M.、Ogihara, T.、Kaneda, Y. 和 Morishita, R.
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Endoh, M., Koibuchi, N., Sato, M., Morishita, R., Kanzaki, T., Murata, Y. and Kaneda, Y: "Fetal gene transfer by intra-uterine injection with microbubble-enhanced ultrasound"Molecular Therapy. 5. 501-505 (2002)
Endoh, M.、Koibuchi, N.、Sato, M.、Morishita, R.、Kanzaki, T.、Murata, Y. 和 Kaneda, Y:“通过微泡增强超声子宫内注射进行胎儿基因转移”分子
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kaneda, Y., Nakajima, T., Nishikawa, T., Yamamoto, S., Ikegami, H., Suzuki, N., Nakamura, H., Morishita, R, and Kotani, H: "HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system"Molecular Therapy. 6. 219-226 (2002)
Kaneda, Y.、Nakajima, T.、Nishikawa, T.、Yamamoto, S.、Ikegami, H.、Suzuki, N.、Nakamura, H.、Morishita, R 和 Kotani, H:“HVJ(血凝病毒
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ueno, T., et al., Kaneda, Y., Matsuda, H.: "Nuclear factor-kB decoy attenuates neuronal damage after global brain ischemia ; a future strategy for brain protection during circulatory arrest"Cardiopulomonary Support and Physiology. 122. 720-727 (2001)
Ueno, T., et al., Kaneda, Y., Matsuda, H.:“核因子-kB 诱饵可减轻全脑缺血后的神经元损伤;循环停止期间脑保护的未来策略”心肺支持和生理学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KANEDA Yasufumi其他文献
KANEDA Yasufumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KANEDA Yasufumi', 18)}}的其他基金
Molecular mechanism of cancer cell pluripotency responding to stress
癌细胞多能性响应应激的分子机制
- 批准号:
24659149 - 财政年份:2012
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of multi-lateral cancer gene therapy by enhancing anti-tumor activity of inactivated Sendai virus particle
通过增强灭活仙台病毒颗粒的抗肿瘤活性开发多方癌症基因疗法
- 批准号:
22300339 - 财政年份:2010
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Transcriptional regulation of osteogenesis using siRNA and its application to bone formation
siRNA对成骨的转录调控及其在骨形成中的应用
- 批准号:
17300153 - 财政年份:2005
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of anti-cancer strategy to increase sensitivity of cancer cells to chemotherapy using siRNA combined with HVJ-E vector
利用siRNA联合HVJ-E载体开发提高癌细胞对化疗敏感性的抗癌策略
- 批准号:
15300163 - 财政年份:2003
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic study of correction of mutated gene in xeroderma pigmentosum group A
着色性干皮病A组突变基因纠正的基础研究
- 批准号:
10470505 - 财政年份:1998
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Isolation and characterization of tumor-specific antigen toward cancer gene therapy
用于癌症基因治疗的肿瘤特异性抗原的分离和表征
- 批准号:
09044306 - 财政年份:1997
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for international Scientific Research
Development of new DDS to individual organs by means of cell technology and its opplication to treatment of human diseases
利用细胞技术开发个体器官新型DDS及其在人类疾病治疗中的应用
- 批准号:
07558126 - 财政年份:1995
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Joint Study on the Therapy of Diseases by Gene Transfer
基因转移治疗疾病的联合研究
- 批准号:
05044170 - 财政年份:1993
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for international Scientific Research
相似国自然基金
厚壁菌门细胞壁肽聚糖及其诱导的NFκB通路炎症反应与肠道菌群结构对儿童非酒精性脂肪性肝病的影响机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
GLP-1受体激动剂通过肠道菌群代谢产物SCFAs抑制PI3K/AKT/NF-κB信号通路抑制糖尿病肾病机制进展研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
IL-36亚家族通过NF-κB通路对儿童腺样体肥大和慢性扁桃体炎的作用及机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
治疗性高碳酸血症对肝巨噬细胞极化及NF-κB通路的影响及其在肝缺血再灌注损伤中的作用
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
蟾毒灵通过SEC13/HMGB1/TLR4/NF-κB轴调控转移生态位抑制乳腺癌骨转移的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于TLR4/NF-κB与PPAR-γ/CD36信号通路间的crosstalk探讨黄芪多糖促进脑出血后血肿吸收的机制
- 批准号:JCZRQN202500623
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
局灶性TBI早期IL-1β调控星形胶质细胞IL-1R1/NF-κB/LCN2信号通路造成脑损伤的机制研究
- 批准号:JCZRYB202500873
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于TLR4/NF-Κb/NLRP3信号通路探讨人参保护T2DM胰岛细胞身份及功能的作用机制
- 批准号:JCZRLH202500005
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
表观调节因子KDM6A通过SYK/NF-κB信号通路调控造血干细胞发育的机制研究
- 批准号:QN25H080012
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
尿毒清颗粒通过调控肠道菌群介导代谢产物-IκB/NF-κB信号轴抗肾间质纤维化机制研究
- 批准号:HZSZ25H270002
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
癌随伴線維芽細胞におけるNFκBシグナル分子の役割
NFκB信号分子在副肿瘤成纤维细胞中的作用
- 批准号:
24K10345 - 财政年份:2024
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
ERβ 重新利用 EZH2 抑制 TNBC 中的致癌 NFκB 信号传导
- 批准号:
10540349 - 财政年份:2021
- 资助金额:
$ 8.13万 - 项目类别:
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
ERβ 重新利用 EZH2 抑制 TNBC 中的致癌 NFκB 信号传导
- 批准号:
10116790 - 财政年份:2021
- 资助金额:
$ 8.13万 - 项目类别:
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
ERβ 重新利用 EZH2 抑制 TNBC 中的致癌 NFκB 信号传导
- 批准号:
10320463 - 财政年份:2021
- 资助金额:
$ 8.13万 - 项目类别:
Genomics of NFκB-mediated gene regulation in multiple sclerosis
多发性硬化症中 NFκB 介导的基因调控的基因组学
- 批准号:
9761429 - 财政年份:2016
- 资助金额:
$ 8.13万 - 项目类别:
Molecular mechanisms of maintenance of breast cancer stem cells by NFκB
NFκB维持乳腺癌干细胞的分子机制
- 批准号:
23701046 - 财政年份:2011
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Inhibition of NFκB activity by MALT1 and its involvement in phenotypic alterations of oral carcinoma cells
MALT1 对 NFκB 活性的抑制及其与口腔癌细胞表型改变的关系
- 批准号:
22592103 - 财政年份:2010
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Therapeutic strategy targeting NFκB-IL6 pathway against progression and paraneoplastic syndrome in prostate cancer
针对前列腺癌进展和副肿瘤综合征的 NFκB-IL6 通路治疗策略
- 批准号:
22591779 - 财政年份:2010
- 资助金额:
$ 8.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




